Lactate Imaging as a Tumour Biomarker
Completed
- Conditions
- Cancer
- Interventions
- Device: Magnetic Resonance Imaging (MRI)
- Registration Number
- NCT01881386
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Brief Summary
This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect.
The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Cohort 1:lymphoma patients
- minimum lesion size of 2cm
- not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone)
Cohort 2:Colorectal patients
- metastatic disease of at least 2cm
- not pretreated
Cohort 3:Phase 1 Drug Development
- minimum lesion size at least 2cm
Cohort 4: Brain
- primary brain tumours receiving radiotherapy and temozolomide
- cerebral lymphoma receiving standard chemotherapy
Exclusion Criteria
- MRI incompatible metal implants
- Claustrophobia
- Inability to tolerate a 40 minute MRI scan
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Phase 1 Magnetic Resonance Imaging (MRI) Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration Lymphoma Magnetic Resonance Imaging (MRI) Lymphoma patients before and after receiving standard CHOP therapy Metastatic Colorectal Magnetic Resonance Imaging (MRI) Patients with metastatic colorectal cancer
- Primary Outcome Measures
Name Time Method Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response 7 and 21 days post treatment
- Secondary Outcome Measures
Name Time Method Reproducibility of MRS lactate measurement Two baseline measurements taken at day -7 to 0 pre-treatment
Trial Locations
- Locations (1)
The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
🇬🇧Sutton, Surrey, United Kingdom